Disappearance of anti-p17 correlates with successful isolation of human immunodeficiency virus and deterioration in clinical status.
Anti-p17 was examined as a human immunodeficiency virus (HIV) marker predicting the onset of the acquired immunodeficiency syndrome (AIDS). Two different comparisons were done: (1) anti-p17 negativity and successful HIV isolation; and (2) anti-p17 negativity and clinical status, using the Centers for Disease Control classification. Anti-p17 negativity was not only significantly correlated with deterioration in clinical status (P less than 0.01), but also with successful HIV isolation (P less than 0.05). HIV isolation was affected by several drugs, e.g. zidovudine. However, the results of the antibody test were not affected. It is significant that anti-p17 can compensate for the defects of virus isolation.
Kageyama
S
S
Department of Virology, Tottori University School of Medicine, Yonago, Japan.
Kurimura
T
T
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000175:diagnosis*; D015153:Blotting, Western; D015683:Gene Products, gag / Q000276:immunology*; D006678:HIV / Q000302:isolation & purification*; D015483:HIV Antibodies / Q000097:blood*; D015488:HIV Antigens / Q000276:immunology*; D006467:Hemophilia A / Q000150:complications; D006801:Humans; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus
D015683:Gene Products, gag; D015483:HIV Antibodies; D015488:HIV Antigens; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C054858:p17 protein, Human Immunodeficiency Virus Type 1